Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Margareta Elg"'
Autor:
Marcus Franz, Mohammad Bohlooly-Y, Malin Palmér, Michael Lichtenauer, Margareta Elg, Bernhard Wernly, Mikael Bjursell, John Pernow, Frank Seeliger, Christian Jung, Qing-Dong Wang, Therese Admyre, Charlotte Frick, Johannes Wikström, Per-Ove Sjöquist, Ann-Katrin Andersson, John Wiseman
Publikováno v:
Journal of Cardiac Failure. 24:470-478
Oxytocin (Oxt) and its receptor (Oxtr) gene system has been implicated in cardiomyogenesis and cardioprotection; however, effects of chronic activation of Oxtr are not known. We generated and investigated transgenic (TG) mice that overexpress Oxtr sp
Autor:
Sofia Zetterstrand, Nicolai Leuchten, Stylianos Kapiotis, Ghazaleh Gouya, Malin Holmberg, Margareta Elg, Ulf Eriksson, Michael Wolzt, Karin Wåhlander, Kajs-Marie Schützer
Publikováno v:
Thrombosis Research. 129:e83-e91
Introduction AZD0837 and ximelagatran are oral direct thrombin inhibitors that are rapidly absorbed and bioconverted to their active forms, AR-H067637 and melagatran, respectively. This study investigated the antithrombotic effect of AZD0837, compare
Publikováno v:
Protein Journal, 31, 5, pp. 353-8
Protein Journal, 31, 353-8
Protein Journal, 31, 353-8
The snake venom protease ecarin from Echis carinatus was expressed in stable transfected CHO-S cells grown in animal component free cell culture medium. Recombinant ecarin (r-ecarin) was secreted from the suspension adapted Chinese Hamster Ovary (CHO
Publikováno v:
British Journal of Haematology. 152:758-765
Summary Orally available direct thrombin inhibitors (DTI) and direct activated factor X inhibitors (DFXaI) may replace vitamin K antagonists in patients needing long-term anticoagulant treatment. We investigated the influence on the fibrin network of
Autor:
Troy C. Sarich, Stig L. Boström, Karin Wåhlander, Michael Wolzt, Ulf G. Eriksson, Margareta Elg, Jeffrey I. Weitz, Marcel Levi, Mia Svensson, Maria Eriksson-Lepkowska
Publikováno v:
Thrombosis and haemostasis, 91(6), 1090-1096. Schattauer GmbH
SummaryThe objectives were to investigate whether activation of the extrinsic coagulation cascade by recombinant factor VIIa (rFVIIa) reverses the inhibition of thrombin generation and platelet activation by melagatran, the active form of the oral di
Autor:
David Gustafsson, Margareta Elg
Publikováno v:
Thrombosis Research. 109:S9-S15
Ximelagatran (Exanta, AstraZeneca) is a novel, oral direct thrombin inhibitor (oral DTI) that is rapidly converted to melagatran, its active form, following absorption. Melagatran has been shown to be a potent, rapidly binding, competitive inhibitor
Publikováno v:
Biopharmaceutics & Drug Disposition. 24:251-257
Background—The objective of this study was to investigate whether the use of a depot formulation would enhance the antithrombotic effect of the direct thrombin inhibitor melagatran. Methods and Results—In a rat venous thrombosis model, animals we
Publikováno v:
Thrombosis Research. 107:163-168
The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats. Thrombus formation was induced in the inferior caval vein b
Publikováno v:
Thrombosis Research. 101:159-170
Melagatran is the active form of the oral, direct thrombin inhibitor, H 376/95, that is under evaluation in clinical trials for the prevention and treatment of thromboembolism. In this study, a single dose, calculated on body weight basis, of antifib
Publikováno v:
Thrombosis Research. 94:187-197
Warfarin limits the synthesis of y-glutamyl carboxylated forms of coagulation factors, factor II, factor VII, factor IX, and factor X, protein C, and protein S and as a result impairs the function of these proteins. In contrast, direct inhibitors of